Roche Discontinues Development Of NK-1 Antagonist For Depression
This article was originally published in The Pink Sheet Daily
Executive Summary
Two Phase II trials for the neurokinin-1 antagonist failed to differentiate between the active controls and placebo, the company says, making it “difficult” to discern a drug effect for the NK-1 agent. Roche will consider out-licensing the product.